Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Staszewski, 2001, Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial, JAMA, 285, 1155, 10.1001/jama.285.9.1155

Sáez-Llorens, 2001, A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1—infected children, Pediatrics, 107, E4, 10.1542/peds.107.1.e4

Saag, 1998, Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults, AIDS, 12, F203, 10.1097/00002030-199816000-00002

Staszewski, 1998, A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects, AIDS, 12, F197, 10.1097/00002030-199816000-00001

Cutrell, 2001, Risk factor analysis for hypersensitivity reactions to abacavir, 1st IAS International Symposium on HIV Pathogenesis and Treatment

Shapiro, 1996, Mechanisms of drug reactions: The metabolic track, Sem Cutaneous Med Surg, 15, 217, 10.1016/S1085-5629(96)80034-4

deShazo, 1997, Allergic reactions to drugs and biologic agents, JAMA, 278, 1895, 10.1001/jama.278.22.1895

Park, 1998, Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective, Chem Res Toxicol, 11, 969, 10.1021/tx980058f

Pohl, 1988, The immunologic and metabolic basis of drug hypersensitivities, Annu Rev Pharmacol Toxicol, 28, 367, 10.1146/annurev.pa.28.040188.002055

McNeely, 1989, Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection, J Am Acad Dermatol, 21, 1213, 10.1016/S0190-9622(89)70332-7

Carr, 1993, Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS), J Allergy Clin Immunol, 91, 683, 10.1016/0091-6749(93)90276-L

Wassef, 1995, Hypersensitivity to zidovudine: Report of a case of anaphylaxis and review of the literature, Clin Infect Dis., 20, 1387, 10.1093/clinids/20.5.1387

Tancrede-Bohin, 1996, Hypersensitivity syndrome associated with zalcitabine therapy, Lancet, 347, 971, 10.1016/S0140-6736(96)91459-2

Bourezane, 1998, DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy, Clin Infect Dis, 27, 1321

Warren, 1998, Nevirapine-associated Stevens-Johnson syndrome, Lancet, 351, 567, 10.1016/S0140-6736(98)24008-6

Mills, 1999, Acute hypersensitivity with delavirdine, Antiviral Ther, 4, 51, 10.1177/135965359900400107

Bossi, 2000, Hypersensitivity syndrome associated with efavirenz therapy, Clin Infect Dis, 30, 227, 10.1086/313629

Bonfanti, 1997, Hypersensitivity reactions during antiretroviral regimens with protease inhibitors, AIDS, 11, 1301, 10.1097/00002030-199710001-00008

Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906

Koopmans, 1995, Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?, AIDS, 9, 217, 10.1097/00002030-199509030-00001

Miller, 1997, Clinical experience with non-nucleoside reverse transcriptase inhibitors, AIDS, 11, S157

Barner, 1998, Nevirapine and rashes, Lancet, 351, 1133, 10.1016/S0140-6736(05)79417-4

Carr, 1996, A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients, AIDS, 10, 635, 10.1097/00002030-199606000-00009

Rietsema, 1997, Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy, Clin Infect Dis, 25, 1268, 10.1086/516976

Rijnders, 1998, Severe allergic reaction after repeated exposure to indinavir, Clin Infect Dis, 26, 523, 10.1086/517108

Dieleman, 1998, Acute respiratory failure associated with the human immunodeficiency virus (HIV) protease inhibitor indinavir in an HIV-infected patient, Clin Infect Dis, 26, 1012, 10.1086/517639

1999, Executive summary of disease management of drug hypersensitivity: A practice parameter, Ann Allergy Asthma Immunol, 83, 665, 10.1016/S1081-1206(10)62890-6

Uetrecht, 1999, New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system, Chem Res Toxicol, 12, 387, 10.1021/tx980249i

Vyakarnam, 2000, Abacavir induced hypersensitivity in HIV infected individuals is associated with an increased frequency of Th0 T cells, AIDS, 14, S65

Kinaciyan, 2000, Hypersensitivity syndrome to abacavir—confirmation by skin testing, Allergy, 55, 153

Escaut, 1999, Abacavir rechallenge has to be avoided in case of hypersensitivity reaction, AIDS, 13, 1419, 10.1097/00002030-199907300-00026

Adkinson, 1984, Risk factors for drug allergy, J Allergy Clin Immunol, 74, 567, 10.1016/0091-6749(84)90108-8

Knowles, 2000, Idiosyncratic drug reactions: The reactive metabolite syndromes, Lancet, 356, 1587, 10.1016/S0140-6736(00)03137-8

Knobel, 2000, Efficacy of a short-term prednisone regimen in nevirapine-associated rash prevention: A double-blind placebo-controlled clinical trial. Results of the GESIDA 09/99 study, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy

Robinson, 2000, Examination of trials to prevent nevirapine (NVP)-associated rash, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy

Thompson, 2000, Interruptions in abacavir dosing are not associated with increased risk of hypersensitivity in the HEART (NZTA4006) study, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy

Frissen, 2001, Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity, AIDS, 15, 289, 10.1097/00002030-200101260-00027